Blog

Single B cell screening accelerates discovery. Biointron reviews its efficiency in identifying potent antibodies versus conventional methods.

VHH antibodies differ from conventional IgGs. Biointron explains structural contrasts and their advantages in therapeutic applications.

PEGS Boston 2025 spotlighted antibody engineering. Biointron reports key event highlights driving protein science and cell therapy innovation.

CAS Annual Conference 2025 showcased antibody progress. Biointron highlights insights shaping discovery, development, and future collaborations.

Biointron’s 2025 Lunch & Learn session with MassBio showcased antibody discovery innovations and practical CRO solutions for researchers.

VHH antibodies, or sdAbs, are derived from camelids. Biointron explores their unique properties and therapeutic potential across biotech.

AI is transforming antibody therapeutics. Biointron explains how data-driven platforms accelerate design, optimization, and clinical translation.

AACR 2025 in Chicago unveiled cancer breakthroughs. Biointron shares highlights advancing antibody research and oncology therapeutics.

Biointron vs. traditional workflows: we compare discovery timelines, showing how our platforms deliver antibodies in weeks instead of months.

Biointron leads in antibody innovation. We highlight how staying ahead of industry trends keeps discovery and development moving forward.

Explore how machine learning improves antibody developability, screening, and optimization by predicting biophysical properties and enhancing drug discovery outcomes.

Licensed CHO cell lines ensure compliant supply. Biointron provides perpetual access for consistent, scalable recombinant antibody production.